Breaking News, Collaborations & Alliances

Taiho and Cullinan Enter Cancer Collaboration

Will develop TAS6417, novel EGFR tyrosine kinase inhibitor

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Taiho Pharmaceutical and Cullinan Oncology have formed an agreement to develop TAS6417, a novel EGFR (epidermal growth factor receptor) tyrosine kinase inhibitor discovered by Taiho.   Under the terms of the agreement, Taiho Pharmaceutical will grant an exclusive, global license ex-Japan for the development and commercialization of TAS6417 to Cullinan Pearl, a newly formed U.S.-based company under the Cullinan Oncology umbrella. Taiho Pharmaceutical will receive an upfront payment, regulatory an...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters